Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin’s Luforbec Launch Leads UK Respiratory Efforts

Lupin UK General Manager Ben Ellis Sets Out Strategy For Fostair Rival

Executive Summary

Following Lupin’s launch of the first UK generic version of Fostair in August, Lupin UK general manager Ben Ellis tells Generics Bulletin how the company is taking full advantage of the opportunity and laying the groundwork for future activities in the respiratory arena.

You may also be interested in...



Legal Certainty Needed On Northern Ireland, Industry Insists

A continuing lack of legal certainty continues to plague suppliers to the Northern Ireland market despite the latest proposals from the EU Commission, UK and European off-patent industry leaders Mark Samuels and Adrian van den Hoven tell Generics Bulletin.

UK Pioneers Tailored Biosimilars Pathway With Fresh Guidance

Updated guidance on the UK’s new licensing pathway for biosimilars – which will typically not require comparative efficacy data – has been published by the MHRA after a stakeholder consultation, receiving a warm welcome from the off-patent industry both locally and internationally.

Lupin Expects Respiratory Ramp Up From Fiscal '22

After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel